Crown Bioscience to Showcase Scientific Expertise at Cambridge UK Symposium: Preclinical Evaluation of Novel Immunotherapies


SAN DIEGO, March 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces it will host its annual Cambridge UK symposium on Thursday, March 15th at The Cambridge Building, Babraham Research Campus.

The scientific symposium, entitled "Perspectives on Oncology Drug Discovery; Immuno-Oncology and the Next Generation", will bring together some of the most influential names in preclinical oncology drug discovery. Distinguished speakers from various multinational pharmaceutical and European biotech companies will present data describing how their latest research efforts provide innovative, unique solutions to advance immunotherapeutics and preclinical pharmacology evaluation.

"I look forward to welcoming the scientific community to our 4th annual Cambridge UK Symposium", said Dr. Sebastian Dempe, CrownBio's Executive Director UK and European business unit. "Immuno-oncology and its preclinical modeling has become a tremendously important focus in cancer research. This year's symposium promises to provide an excellent opportunity for networking and scientific discussions around the latest advances in immuno-oncology research."

Register to attend the symposium here,  

About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. 

Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Crown Bioscience Inc. via Globenewswire




Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

3Gtms Positioned in the Niche Players Quadrant of the Gartner Magic Quadrant for Transportation Management Systems21.3.2018 15:00Pressmeddelande

Inclusion marks the first time 3Gtms has been named to the Magic Quadrant SHELTON, Conn., March 21, 2018 (GLOBE NEWSWIRE) -- 3Gtms, Inc., a global provider of Tier 1 transportation management software, today announced it has been positioned by Gartner, Inc. in the Niche Players quadrant of the report, Magic Quadrant for Transportation Management Systems*. This is the first time 3Gtms has been positioned within the Magic Quadrant. According to the report, the research "focuses on holistic multimodal domestic TMSs for use by shippers (such as manufacturers, retailers, distributors and wholesalers) or non-asset-based, third-party logistics (3PL) organizations." Key criteria for the 2018 Magic Quadrant included: The breadth of the TMS; depth of the TMS; usability and adaptability; global go-to market strategy and offering; partner ecosystem; vision, thought leadership, roadmap, and track record; and a compelling SCE convergence strategy. The full report is available at no charge at the 3Gt

Further UHNWI Investment To Support FinTech Entrepreneur Zichain's Growth and Innovation21.3.2018 14:46Pressmeddelande

Zichain / Further UHNWI Investment To Support FinTech Entrepreneur Zichain's Growth and Innovation . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. ZURICH, Switzerland, March 21, 2018 (GLOBE NEWSWIRE) -- Zichain, a Switzerland-based digital asset management company, is pleased to announce that it has secured an USD 1.2m investment from a syndicate of UHNW Hong-Kong based investors, supporting further development of its unique cryptocurrency products. The deal was confirmed while the Company was participating at the Goldman Sachs 2018 Disruptive Technology Symposium, held in London on 20-21 March. As a pioneer of the cryptocurrency index industry, Zichain has enjoyed exponential growth with the Company now taking a leading role in the creation of digital asset management industry. Zichain is focused on the development of three key products: Blockchain Asset Management Platform (BAMP), a unique and convenien

Addivant Announces Price Increases on Hindered Amine Light Stablizers21.3.2018 14:38Pressmeddelande

DANBURY, Conn., March 21, 2018 (GLOBE NEWSWIRE) -- Effective immediately or as contract terms allow, Addivant(TM), a global leader in polymer additives, is increasing the price of Hindered Amine Light Stabilizers by up to 15%. The adjustment is driven by raw material cost increases and market conditions. About Addivant(TM) Addivant(TM) is an innovator in the field of polymer additives, developing customized solutions that provide customers enhanced application performance, safe handling, and reduction in cost of use. The company is recognized industry-wide for its extensive portfolio of specialty additives including antioxidants, light stabilizers, rubber additives, polymer modifiers, metal deactivators, polymerization inhibitors and intermediates. Addivant is an international company, with 11 plants in five regions as well as research, manufacturing and sales facilities around the globe. Addivant maintains its global headquarters in Connecticut, USA with regional headquarters in: Al J

VistaJet Connects Customers and Their Passions With the Global British Polo Day Tour21.3.2018 14:17Pressmeddelande

Customers to join the most prestigious worldwide polo tournament LONDON, March 21, 2018 (GLOBE NEWSWIRE) -- VistaJet, the first and only global private aviation company, will be offering customers the opportunity to enrich their passion for polo as the company partners with British Polo Day for the 2018 worldwide tournament, following a successful inaugurate partnership last year. The sport is a key interest for many of VistaJet's customers, both as spectators and riders, and is in line with 39% of the world's animal-loving Ultra High Net Worth population having a passion for horses*. VistaJet continuously develops and offers exceptional experiences for its customers inspired by their true passions, including art, sport and travel, across all cultures worldwide. Its global partnership with British Polo Day will offer customers an exclusive opportunity to enjoy one of their most cherished interests by watching some of the sport's top players, including the world's number one player Adol

Immunicum AB: Invitation to Investor Events21.3.2018 14:00Pressmeddelande

Press Release 21 March 2018 Immunicum AB: Invitation to Investor Events Immunicum AB (publ; IMMU.ST) a biopharmaceutical company advancing a novel, immune-priming cancer treatment against a variety of solid tumors, announced today that the Company will host two investor events in April. At both events, Carlos de Sousa, CEO of Immunicum, will give the current corporate presentation and he and other members of the Immunicum leadership team will be available for a question and answer session. Stockholm Date: Wednesday, April 11, 2018 Time: 18:00 - 20:00 CET Location: Citykonferensen Ingenjörshuset Room: Styrelserummet Malmskillnadsgatan 46 111 84 Stockholm Gothenburg Date: Wednesday, April 18, 2018 Time: 18:00 - 20:00 CET Location: First Hotel G Restaurant Orkidé Nils Ericsonplatsen 4 411 03 Gothenburg To register to attend the events, please send an email to with your full name and the selected location (Stockholm or Gothenburg). For more information, please contact:

Immunicum AB: Inbjudan till investerarkvällar21.3.2018 14:00Pressmeddelande

Pressmeddelande 21 mars 2018 Immunicum AB: Inbjudan till investerarkvällar Immunicum AB (IMMU.ST), ett bioteknikbolag som utvecklar nya immunostimulerande cancerbehandlingar för ett antal solida tumörformer, meddelade idag att bolaget kommer att ordna två investerarkvällar i april. Vid båda tillfällena kommer Immunicums VD Carlos de Sousa att hålla en presentation av det dagsaktuella läget i bolaget, och han och övriga medlemmar i ledningen är tillgängliga för att svara på frågor. Stockholm Datum: onsdag, 11 april 2018 Tid: 18:00-20:00 CET Plats: Citykonferensen Ingenjörshuset Sal: Styrelserummet Malmskillnadsgatan 46 111 84 Stockholm Göteborg Datum: onsdag, 18 april 2018 Tid: 18:00-20:00 CET Plats: First Hotel G Sal: Orkidé i restaurangen Nils Ericsonplatsen 4 411 03 Göteborg För att delta i investerarkvällarna, skicka ett mejl till med ditt fullständiga namn och orten där du vill delta (Stockholm eller Göteborg). För ytterligare information kontakta: Carlos de So

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum